Orchid Pharma targets US Exblifep deal in FY27

What Orchid is trying to close in the US

Orchid Pharma Ltd said it is in advanced discussions to out-license enmetazobactam in the United States, positioning the deal as a potential commercial breakthrough in the world’s largest pharmaceutical market. The Chennai-based company told investors that conversations with potential partners have progressed to an advanced stage. Management indicated a deal could be finalised in the near term. Whole-time director Mridul Dhanuka said on a recent earnings call that the company hopes the discussions will close in this quarter or the coming quarter. For Orchid, the US licensing outcome is central because it can determine how quickly the product scales in a market where partner capability and hospital access matter.

Why the launch can move quickly after signing

Orchid said a US launch could be quick once an agreement is executed because regulatory approval is already secured. This reduces one of the major uncertainties that typically slows down commercialisation timelines. The company’s comments suggest that the remaining work is largely commercial and operational, including partner selection, distribution readiness, and launch planning. Management also acknowledged that US deal processes can take time due to partner due diligence of the dossier and related documentation. Even so, Orchid reiterated that it is in advanced discussions with several companies and is targeting closure within this year.

Global licensing push beyond the US

Outside the United States, Orchid said it is negotiating licensing arrangements across Japan, Russia, Latin America, and Southeast Asia. The company described these discussions as being at different stages, ranging from term sheets to definitive agreements. Dhanuka told investors that several of these negotiations are in advanced discussion and Orchid hopes to sign multiple deals this year. In response to a question specifically about Japan, management said it is in advanced negotiations in several countries including Japan, but long-term contracts are taking longer to finalise than initially anticipated. The company added that it hopes to have a definitive agreement shortly.

India distribution: Cipla partnership

In India, Orchid has partnered with Cipla to distribute enmetazobactam. The India arrangement provides a domestic commercial pathway while the company works to expand licensing and launch footprints across other geographies. Management also noted that performance in India has aligned with projections, while penetration in the institutional market is still behind.

Exblifep timeline and expectations outlined by management

Management commentary included a deal timeline and launch expectations for Exblifep, the brand referenced for enmetazobactam. Orchid expects at least one out-licensing deal within Q1 FY27. It also said only around 50% of targeted markets are expected to be signed within six months, indicating that closing multiple territories will likely be staggered. Orchid further revised its peak sales expectation to year 4 to 5 post-launch, from an earlier view of year 3. The company reiterated a lifetime sales potential of USD 1 to 2 billion over the patent life.

US sterile fill-finish strategy: investment and product focus

Alongside the licensing discussion, Orchid described a material strategic decision on US manufacturing and product entry. It is investing in fill-finish and formulation development capabilities at its existing US FDA-approved sterile cephalosporin site. The company is targeting 5 to 6 large sterile products that it believes cover around two-thirds of the US cephalosporin market opportunity, which it sized at USD 1.2 billion. Orchid also outlined the intended product mix as approximately 50% near-patent-expiry patented products, 30% sterile generics, and 20% oral products. The message to investors was that this investment is designed to support a more active and sustained US presence.

ANDA filing plan and the “dual site” de-risking approach

Orchid said it will file its first two US ANDA candidates via an alternate contract manufacturing organisation (CMO) to avoid delays while its own site awaits inspection or approval steps. It identified the first two candidates as Ceftazidime-Avibactam and Ceftaroline. The company plans to add the Orchid site as an alternate manufacturing site post-approval. Management also stated that key pipeline products such as Teflaro and Avycaz are nearing US filings, with partner agreements expected soon, and that filings are anticipated this year or early next year.

How Orchid’s rights position changed after Allecra

Orchid described a strategic reversal in October 2025, when it reacquired 100% of the global rights and assets of Allecra Therapeutics, transforming it from a royalty-earning partner into the sole proprietor of a de-risked, FDA-approved drug. The company said it has acquired global rights to enmetazobactam and the Exblifep trademark from Allecra following Allecra’s insolvency, giving Orchid control over the regulatory and commercial strategy worldwide once the acquisition is formally completed. It also noted the transaction is subject to certain conditions and is expected to be completed within the next three months.

Key facts at a glance

Market impact: what investors are watching

For investors, the central variable is whether Orchid can convert “advanced discussions” into a definitive US partner agreement, given the market’s scale and the operational requirements of hospital-focused antibiotics. The company’s emphasis on quick launch post-signing highlights that regulatory clearance is not the key bottleneck. Instead, the deal structure, partner capabilities, and commercial execution will determine how quickly the product can be placed and scaled.

The parallel US sterile fill-finish investment and ANDA filing strategy adds a second track that management is positioning as a way to build a broader, sterile-focused US portfolio. Orchid acknowledged it has not meaningfully participated in the US market for about six years post-NCLT, despite having the only Indian US FDA-approved sterile cephalosporin facility, and said the new approach is intended to address that gap.

Conclusion

Orchid Pharma says it is close to concluding a US out-licensing arrangement for enmetazobactam, with management guiding that discussions could close this quarter or the next and reiterating a target to sign within the year. Beyond the US, the company is negotiating across multiple regions including Japan and Russia, while maintaining a Cipla distribution partnership in India. The next key update for markets is whether ongoing term sheets and advanced discussions progress into definitive agreements, starting with at least one deal expected within Q1 FY27.